Edwards Lifesciences Corporation $EW Stock Purchased by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC raised its stake in Edwards Lifesciences Corporation (NYSE:EW) by 125.0% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 45,000 shares of the medical research company’s stock after purchasing an additional 25,000 shares during the period. Edwards Lifesciences comprises 2.4% of Sivik Global Healthcare LLC’s portfolio, making the stock its 18th largest holding. Sivik Global Healthcare LLC’s holdings in Edwards Lifesciences were worth $3,884,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. NorthCrest Asset Manangement LLC raised its stake in shares of Edwards Lifesciences by 87.8% during the 3rd quarter. NorthCrest Asset Manangement LLC now owns 7,354 shares of the medical research company’s stock worth $619,000 after buying an additional 3,439 shares in the last quarter. GK Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at approximately $26,000. Wedmont Private Capital boosted its stake in shares of Edwards Lifesciences by 3.4% in the third quarter. Wedmont Private Capital now owns 13,513 shares of the medical research company’s stock valued at $1,138,000 after buying an additional 444 shares in the last quarter. WoodTrust Financial Corp purchased a new stake in shares of Edwards Lifesciences in the third quarter valued at approximately $904,000. Finally, GAMMA Investing LLC grew its holdings in Edwards Lifesciences by 11.7% during the third quarter. GAMMA Investing LLC now owns 12,599 shares of the medical research company’s stock worth $1,088,000 after acquiring an additional 1,318 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction dated Thursday, October 8th. The shares were sold at an average price of $85.65, for a total value of $53,017.35. Following the sale, the vice president directly owned 40,034 shares in the company, valued at $3,428,912.10. The trade was a 1.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 544 shares of the business’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the sale, the senior vice president owned 14,868 shares in the company, valued at $1,353,880.08. This represents a 3.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 5,045 shares of company stock valued at $451,596. Insiders own 0.31% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on EW shares. JPMorgan Chase & Co. increased their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Friday, July 17th. BTIG Research restated a “buy” rating and set a $110.00 target price on shares of Edwards Lifesciences in a research report on Friday, September 11th. Barclays raised shares of Edwards Lifesciences to a “strong-buy” rating in a research note on Wednesday, October 7th. Finally, TD Cowen reiterated a “buy” rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and a consensus price target of $100.27.

Edwards Lifesciences Price Performance

Shares of NYSE:EW traded down $0.70 during trading on Tuesday, hitting $85.69. 977,864 shares of the stock were exchanged, compared to its average volume of 4,496,346. The company has a market cap of $49.34 billion, a PE ratio of 49.24, a P/E/G ratio of 2.23 and a beta of 0.87. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The company has a fifty day moving average price of $88.67 and a two-hundred day moving average price of $86.22. Edwards Lifesciences Corporation has a 12-month low of $72.40 and a 12-month high of $96.29.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. The firm had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%. Edwards Lifesciences’s quarterly revenue was up 13.6% on a year-over-year basis. During the same period last year, the business posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, analysts forecast that Edwards Lifesciences Corporation will post 3.00 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.

Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.